5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Oral EPI-7386 in patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Pachynski, R. K.; Iannotti, N.; Laccetti, A. L.; Carthon, B. C.; Chi, K. N.; Smith, M. R.; Vogelzang, N. J.; Tu, W.; Kwan, E. M.; Wyatt, A. W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Effect of Janus kinase (JAK) signaling inhibition on lineage plasticity and drug sensitivity in castrate resistant prostate cancer
    Meeting Abstract

    Zaidi, S.; Chan, J. M.; Love, J.; Zhao, J.; Setty, M.; Lawrence, K.; Gopalan, A.; Goodrich, D.; Morris, M. J.; Chen, Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1 efficacy and pharmacodynamic results of exicorilant + enzalutamide in patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Morris, M. J.; Linch, M. D.; Crabb, S. J.; Beer, T. M.; Heath, E. I.; Gordon, M. S.; De Bono, J. S.; Pashova, H. I.; Tudor, I. C.; Greenstein, A. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Barriers to guideline-concordant use of bone modifying agents for prostate cancer
    Meeting Abstract

    Mitchell, A. P.; Persaud, S.; Chimonas, S.; Salner, A. L.; Palyca, P.; Farooki, A.; Ostroff, J. S.; Morris, M. J.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Second interim analysis (IA2) of MAGNITUDE
    Meeting Abstract

    Efstathiou, E.; Smith, M. R.; Sandhu, S.; Attard, G.; Saad, M.; Olmos, D.; Castro, E.; Roubaud, G.; Gomes, A. J.; Small, E. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Impact of run-in treatment with abiraterone acetate and prednisone (AAP) in the MAGNITUDE study of niraparib (NIRA) and AAP in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations
    Meeting Abstract

    Castro, E.; Chi, K. N.; Sandhu, S.; Olmos, D.; Attard, G.; Saad, M.; Gomes, A. J.; Rathkopf, D. E.; Smith, M. R.; Kang, T. W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • First look at the baseline characteristics of participants in IRONMAN, the international registry for men with advanced prostate cancer
    Meeting Abstract

    Mucci, L. A.; Vinson, J.; Gerke, T. A.; Hyslop, T.; Howard, L.; Dreicer, R.; Rathkopf, D. E.; Chi, K. N.; Esteban, E.; Enting, D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy
    Meeting Abstract

    Bryce, A. H.; Piulats, J. M.; Reaume, M. N.; Ostler, P. J.; McDermott, R. S.; Gingerich, J. R.; Pintus, E.; Sridhar, S. S.; Abida, W.; Daugaard, G.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Changes in planned disease management after piflufolastat F(18) PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study
    Meeting Abstract

    Pouliot, F.; Gorin, M. A.; Rowe, S. P.; Saperstein, L.; Denes, B. S.; DiPippo, V. A.; Stambler, N.; Morris, M. J.; Siegel, B. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Management of patients with advanced prostate cancer. Part I: Intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
    Journal Article

    Gillessen, S.; Bossi, A.; Davis, I. D.; de Bono, J.; Fizazi, K.; James, N. D.; Mottet, N.; Shore, N.; Small, E.; Smith, M.; more...
    European Urology (2023)

    Fulltext@MSK | Save